


VU6000918

Cat. No.:	HY-139044		
CAS No.:	2101737-32-8		
Molecular Formula:	C ₁₈ H ₁₇ F ₂ N ₅ OS		
Molecular Weight:	389.42		
Target:	mAChR		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (320.99 mM; Need ultrasonic)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.5679 mL	12.8396 mL	25.6792 mL
5 mM	0.5136 mL	2.5679 mL	5.1358 mL
10 mM	0.2568 mL	1.2840 mL	2.5679 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

VU6000918 is a muscarinic acetylcholine (M4) positive allosteric modulator, with an EC₅₀ of 19 nM for hM4^[1].

IC₅₀ & Target

EC₅₀: 19 nM (hM4)^[1].

In Vitro

VU6000918 demonstrates statistically significant AHL reversal (18%) from a low oral dose of 0.03 mg/kg and reaches maximal reversal (74%) from a 3 mg/kg dose, with a resulting in vivo plasma EC₅₀ of 74 nM (0.66 nM unbound) based on terminal concentrations measured in the study animals (1.5 hr post-administration of 17j)^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. James C Tarr, et al. Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides. *Bioorg Med Chem Lett*. 2017 Jul 1;27(13):2990-2995.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA